Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.

Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after ...

At the Big Ten CRC Summit, VK Gadi, MD, PhD, explained why functional drug testing and genomic profiling should be used ...

The investigators concluded that AZUR-1 “demonstrates sustained clinical complete responses after dostarlimab monotherapy in ...

A multidisciplinary panel discusses the effects of GLP-1 RA use during breast cancer care along with insurance denials, costs ...

Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point. Although the phase 2 EVITA trial ...

First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer.

Translating laboratory discoveries into clinical benefit for patients with breast cancer increasingly depends on combining ...

The next-generation KRAS G12C inhibitor divarasib significantly prolonged progression-free survival (PFS) and overall ...

Based on data from the phase 3 SAFFRON trial, osimertinib plus savolitinib may establish a new global standard of care in this EGFR-mutated NSCLC population. Data from the phase 3 Krascendo 1 trial ...

Sone-Ve significantly improved OS vs investigator’s choice in previously treated CLDN18.2-positive gastroesophageal carcinoma ...

In October 2026, the Vatican announced that Pope Leo XIV had undergone a right lower lobectomy to remove a lung nodule that ...